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Abstract
Background
The disease course of human immunodeficiency virus (HIV) is often altered by existing or
newly acquired coincident infections.
Methodology/Principal Findings
To assess the influence of pre-existingWuchereria bancrofti infection on HIV progression,
we performed a case-controlled treatment study of HIV positive individuals with (FIL+) or
without (FIL-)W. bancrofti infection. Twenty-eight HIV+/FIL+ and 51 matched HIV+/FIL-
subjects were treated with a single dose of diethylcarbamazine and albendazole (DEC/Alb)
and followed for a year at regular intervals. Sixteen of the HIV+/FIL+ subjects (54%) and
28 of the HIV+/FIL- controls (57%) were on antiretroviral therapy (ART) during the study.
Following treatment, no differences were noted in clinical outcomes between the 2 groups.
There also was no significant difference between the groups in the HIV viral load at
12 months as a percentage of baseline viral load (HIV+/FIL+ group had on average 0.97
times the response of the HIV+/FIL- group, 95% CI 0.88, 1.07) between the groups. Further-
more, there were no significant differences found in either the change in viral load at 1, 3, or
6 months or in the change in CD4 count at 3, 6, or 12 months between the 2 groups.
Conclusions/Significance
We were unable to find a significant effect ofW. bancrofti infection or its treatment on HIV
clinical course or surrogate markers of HIV disease progression though we recognized that
our study was limited by the smaller than predicted sample size and by the use of ART in
half of the patients. Treatment ofW. bancrofti coinfection in HIV positive subjects (as is
usual in mass drug administration campaigns) did not represent an increased risk to the
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subjects, and should therefore be considered for PLWHA living inW. bancrofti endemic
areas.
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Author Summary
In people living with HIV infection, simultaneous infections can adversely affect HIV dis-
ease. This has been seen with bacterial (tuberculosis), viral (cytomegalovirus), and parasit-
ic infections (toxoplasmosis). Lymphatic filariasis is caused by a thin thread-like parasite
that lives in the lymph vessels of infected people. It can cause significant disability. This in-
fection is found in much of the same areas that high levels of HIV infection. We were in-
terested in knowing if lymphatic filariasis changed the course of HIV infection in people
with both diseases. In this study, the authors enrolled people in India who were living with
HIV who either had or didn’t have filarial infection. All patients were treated for filariasis
with 2 drugs, and then were followed for 1 year to see how their HIV disease progressed.
No difference in HIV disease progression was found between the groups that did or did
not have filariasis before treatment. The patients with HIV did well with the medicine
for filariasis.
Introduction
As the HIV epidemic continues in many parts of the world, more attention is being focused on
strategies for prevention and management of HIV infection. In addition to highly active antire-
troviral therapy (ART), the immune interactions between HIV and non-HIV co-infections
have been examined. Several groups have examined the interaction of helminth infections with
HIV, and many of these studies have been recently reviewed[1–3]. Some studies have shown
that patients with HIV and concomitant helminth infections have higher viral loads which de-
crease upon anthelmintic treatment [4,5] whereas others have shown no effect of coincident
helminth infections on viral load, CD4 count or HIV disease progression [6–9].
Few studies have looked at the interaction of filarial infections with HIV. In studies of pa-
tients with Onchocerca volvulus infection with and without HIV, those with HIV were found to
have more significant skin disease [10] and were less likely to have antibodies to onchocercal
antigens [11]. Despite these differences, HIV/Onchocerca-co-infected patients were as capable
as HIV negative onchocerciasis patients of responding to treatment with ivermectin [12]. A co-
hort of HIV+ individuals coinfected withWuchereria bancrofti (Wb) have been followed in
Tanzania [13–15]. When treated with diethylcarbamazine (DEC), those who were circulating
filarial antigen (CFA) positive (a surrogate for active infection) had a decrease in HIV viral
load at 12 weeks whereas those who were CFA negative had an increase in viral load [14] fol-
lowing DEC administration. In a previous study, we have looked at the coinfection prevalence
rates in India by surveying serum samples of HIV infected patients for filaria antigens. We
found a prevalence of 5–9.5% of filarial antigenemia in HIV+ patients, similar to the preva-
lences found in the HIV negative population in the same region [16].
None of the studies to date has looked at the interactions between HIV and helminths out-
side of Africa. According to data from the Indian National AIDS Control Organization the
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2011 estimated prevalence of HIV in adults in India was 0.27%. This results in about 2.1 mil-
lion people infected with HIV [17]. The state of Tamil Nadu, in the south, has a higher than av-
erage adult HIV prevalence, with an estimated 133,000 infected adults [18]. Use of
antiretrovirals is still rolling out in this population: as of January 2012, only 486,173 people
were on ART [19].
Methods
Ethics statement
This study was approved by the Institutional Review Board of NIAID, the Ethics Review
Boards at the Tuberculosis Research Centre (TRC, now the National Institute for Research on
Tuberculosis) and YRGCare as well as by the Health Ministry Screening Committee of the
Government of India. All subjects provided written informed consent.
Study design
This was a prospective matched case-control study designed to compare HIV replication and
progression of clinical disease between patients co-infected with HIV andWb infection and pa-
tients that were HIV-positive but without Wb infection.
Study medication
Albendazole was provided by Glaxo-Smith-Kline (GSK, Middlesex, UK) as part of the Global
Program to Eliminate Lymphatic Filariasis (GPELF). Diethylcarbamazine (DEC) was from
GSK-India, which is the same source that provided DEC for the GPELF. The study medication
was stored at the two sites in Chennai where the study was conducted in the pharmacy under
the control of a pharmacist or nurse. The study staff directly observed subjects as they took
the medications.
Study subjects
Existing or new adult subjects18 years of age cared for at clinics run by YRGCare or the TRC
at their sites in Chennai, India were recruited for this study. These subjects were all HIV+ by
enzyme-linked immunosorbent assay (ELISA) and Western Blot testing. About half of those
enrolled were on antiretroviral medication. Subjects were eligible if they were willing to partici-
pate and could give informed consent. Pregnant or lactating women were excluded, as were
subjects that were acutely ill, had a hemoglobin<9 g/dl for women and<10 g/dl for men, had
AST or ALT elevations>5 times the upper limit of normal, had evidence of acute HIV infec-
tion, or had active or known untreated tuberculosis.
Subjects willing to participate were screened for filarial antigenemia using a rapid immuno-
chromatographic test (Filariasis Now, Binax, Portland, ME). Those found to be filarial antigen
positive (cases) were enrolled, and data collected included demographics and clinical details.
Each “case” who fulfilled the other inclusion criteria was matched for purposes of comparison
with up to two HIV+, Wb-negative patients (controls) from the screened clinic cohort matched
for age (within ±5 years), gender, viral load (matched to within ± 0.5 log HIV RNA copies),
CD4 counts (matched to within the same range:<50; 50–100; 101–200; 201–300;>300) and
for anti-viral regimes (that were similar enough in efficacy for purposes of effective
comparison).
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Study procedures
At screening, all subjects had a thorough clinical assessment: a history and physical examina-
tion, blood for complete blood counts, liver functions (ALT, AST), CD4 count, serum storage
for later analyses; stool samples were taken for examination of parasites. Female subjects un-
derwent a urine pregnancy test. Potentially eligible subjects underwent a viral load. All enrolled
subjects received a single dose of the combination of DEC (300 mg)/albendazole (400 mg).
Subjects were followed at 1, 3, 6 and 12 months after receipt of the medication. At each visit,
subjects were queried as to their interim history: any illnesses, new diagnoses, or changes in
medications were noted. At all visits, a CBC and HIV viral load was scheduled; CD4 counts
were scheduled at 3, 6 and 12 months. At the 12 month visit, all patients were retested for filari-
al antigenemia and, if positive, offered retreatment with DEC and albendazole.
Laboratory assays: Filarial antigen status was assessed in real time by immunochromato-
graphic card test (Filariasis Now Binax, Portland, ME). Samples were stored, batched and
grouped to run theWuchereria bancrofti antigen ELISA (Tropbio Townsville, Australia) to
quantitate levels of circulating filarial antigens. Filaria specific IgG and IgG4 levels were mea-
sured by ELISA as previously described [20].
Study endpoints
The original endpoints of the study were the change in HIV viral load and the difference in
clinical status between the cases and the controls one year after treatment with DEC and alben-
dazole. We also examined the change in HIV viral load, CD4 counts and hemoglobin through-
out the study.
Statistical analysis
Differences in groups were tested by Wilcoxon-Mann-Whitney (WMW) test (for continuous
responses), Fisher’s exact test (for categorical responses) and Wilcoxon signed rank (WSR) test
for paired analyses. Additionally, a version of the WMW stratified by ART status was used
[21].
Viral load was analyzed on a log10 scale. According to the guidelines for HIV treatment,
baseline CD4 count was put into 1 of 4 categories:<200, 200–350, 350–500 and500. Patients
were classified as either on or not on ART during the study. Two patients started the study not
on ART and began ART during the course of the study, and those two patients are treated as
on ART for the main analyses. As a sensitivity analysis, all analyses were repeated with those
two patients reclassified as off ART to see if there were substantial differences in the results.
A linear model was used to assess the association of the response log percentage of baseline
viral load at 1 year with filarial co-infection, adjusting for other covariates (ART status, baseline
hemoglobin, baseline CD4 count and baseline viral load) by including them in the model as
main effects. We report filarial coinfection effects in terms of a multiplicative factor acting on
the response (percentage of baseline viral load at 1 year) in the model. Similar linear models
were done at 1 month, 3 months and 6 months, as well as with CD4 counts. All tests were
2-sided and at a significance level of 0.05. All analyses were conducted using the software R
(version 2.15.2).
Results
Baseline
376 subjects were screened (Fig. 1). Twenty-eight subjects were found to be filarial positive
(HIV+/FIL+). These were matched with 52 HIV positive subjects who did not have Wb
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infection (filarial-negative) (HIV+/FIL-) as controls (one control subject had no baseline viral
load). Baseline summary statistics are given in Table 1. Because the groups are matched, as ex-
pected there are no significant differences between the groups (Table 1, Fig. 2). Many subjects
in both groups took co-trimoxazole and a multivitamin throughout the study. Less than 10% of
subjects were positive for ova or parasites on stool exam, so this variable was not included in
the analyses.
Clinical evaluation
The treatment with DEC/albendazole was well tolerated in our study subjects, with no adverse
events attributed to the study medication. There were several unrelated significant illnesses in
the study (1 HIV+/FIL+ subject developed malaria at 3.5 months, another HIV+/FIL- subject
developed tuberculous meningitis at 4 months with leg weakness as a sequelae, and a third
HIV+/FIL- subject had pulmonary tuberculosis and underwent a hysterectomy for an unrelat-
ed problem. One death occurred at 4.5 months in a HIV+/FIL+ subject who had been diag-
nosed and treated for pulmonary tuberculosis and cryptococcal meningitis prior to starting the
study, and who had also been on ART for 1 year before enrollment. His death was attributed to
a recurrence of the cryptococcal meningitis and possible tuberculoma. In addition to the death,
7 HIV+FIL+ subjects were lost to follow-up as were 2 HIV+/FIL- controls (Fig. 1), and addi-
tionally some subjects missed some viral load measurements at intermediate time points. No
Fig 1. Consort diagram.
doi:10.1371/journal.pntd.0003622.g001
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other subjects developed significant opportunistic infections while on treatment, although sev-
eral had histories of tuberculosis or other infections prior to enrollment that had been treated.
Laboratory evaluation
Following DEC/Alb, subjects were followed at 1, 3, 6, and 12 months following drug adminis-
tration. At one year, the planned primary endpoint, we have VL measurements on 20 (HIV+/
FIL+) and 49 (HIV+/FIL-) subjects. One of the HIV+/FIL+ died. There was no significant dif-
ference between the two groups (HIV+/FIL+ and HIV+/FIL-) in the percent of baseline viral
load at one year (counting the subject that died as ranked highest for response, and the
Table 1. Demographics.
ENROLLED
HIV+/FIL+ HIV+/FIL- Two-sided p-value
Number 28 52^ NA
Gender
N (%) female 12 (43%) 23 (44%) 1.00 (Fisher’s exact)
Language
N (%) Tamil 19 (68%) 38 (73%) 0.33 (Fisher’s exact)
N (%) Telegu 9 (32%) 11 (21%)
N (%) other/N/A 0 (0%) 3 (6%)
Age
GM (SD) 34.0 (6.9) 34.8 (6.6) 0.5 (WMW)
N (%) on ART 16 (57%) 28 (54%)* 1.00 (Fisher’s exact)*
Baseline Labs GM (95% CI)
Hematology
Hgb 12.7 (11.8, 13.5) 13.1 (12.7, 13.4) 0.39 (WMW)
WBC 6.4 (5.5, 7.4) 6.2 (5.7, 6.8) 0.76 (WMW)
% EOS 6.0 (4.3, 8.3) 4.8 (3.9, 5.9) 0.23 (WMW)
Plts 274 (220, 342) 227 (208, 284) 0.18 (WMW)
Liver function
ALT 25 (21, 29) 26 (22, 30) 0.99 (WMW)
AST 26 (22, 29) 28 (24, 31) 0.66 (WMW)
HIV monitoring
CD4 Count 370 (281, 488) 443 (381, 515) 0.33 (WMW)
VL (log10) 3.76 (3.32, 4.21) 3.68 (3.37, 3.99)^ 0.86 (WMW)
Filaria antigen
Circulating Ag 1123 (590, 2138)$ 1.7 (1, 2.6)$ <0.0001 (WMW)
Abbreviations: HIV: Human Immunodeficiency Virus; FIL: Filaria (W. bancrofti antigen) positive; GM:
geometric mean; SD: standard deviation; WMW: Wilcoxon-Mann-Whitney; ART: highly active antiretroviral
therapy, N/A: Not available; %: percent. Hgb: Hemoglobin (gm/dL); WBC: White blood cell count (x 103/mm3);
EOS: eosinophils; Plts: platelet count (x103/uL); ALT: alanine transaminase (SGPT, IU/L); AST: aspartate
transaminase (SGOT, IU/L); VL: viral load; Ag: antigen.
^ 52 subjects were enrolled, but 1 subject did not have baseline HIV viral load value done. These statistics
are on all 52 except for the viral load.
* In addition to the 28 subjects who got ART throughout, there were 2 (3.8%) subjects who got ART only part
of the time during the study. Fisher’s exact test excluded those 2 subjects.
$ Measured on only n = 12 in the HIV+/FIL+ group and n = 39 in the HIV+/FIL- group.
doi:10.1371/journal.pntd.0003622.t001
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2 subjects that got ART for part of the time as having ART) by stratified WMW test, stratified
by ART (p = 0.41) (Fig. 2, Fig. 3). To estimate an effect of HIV+/FIL+, we ran a linear model
on the log percent change. We find that, controlling for ART, on average those with HIV+/FIL+
have about 0.97 times the percent change of viral load at one year than those with HIV+/FIL-
(95% CI 0.88, 1.07). Repeating the analysis at different time points post baseline, we get similar
results. We get similar results in all these models if we additionally control for baseline hemo-
globin, baseline CD4 count and baseline viral load, or if the 2 subjects who started ART after
baseline are treated as not on ART.
When we examined the subset of subjects (n = 27) who were not on antiretrovirals (9
HIV+/FIL+ subjects, 18 HIV+/FIL- subjects), we found that at 1 month following DEC/Alb,
there was a significant difference in the percent change of the HIV log10 viral load between the
2 groups with the HIV+/FIL+ subjects showing a GM increase of 5.1% [95%CI −3.7 to 13.6%]
compared to the HIV+/FIL- subjects who showed a change of −2.2% [95% CI −6.3 to 2.0%];
p = 0.05 WMW. This difference in the changes in viral loads was not sustained throughout
the remaining 3, 6 or 12 month time-points (at 12 months, the HIV+/FIL+ subjects not on
Fig 2. CD4 count and viral load comparisons at baseline and 1 year.Comparison of CD4 and viral load (VL) at baseline (A CD4 [count/dL]),B log VL
[log10 RNA Copies]) and at 1 year (C CD4 count,D log VL) between HIV+/FIL+ cases and HIV+/FIL- controls.
doi:10.1371/journal.pntd.0003622.g002
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antiretrovirals [n = 9] had a mean change of −1.0 logs [95% CI −5.2 to 3.2], and the HIV+/FIL-
subjects (n = 22) had a mean change of 2.6 logs [95% CI −7.9 to 13.1] p = 0.2).
CD4 counts were assessed at 3, 6 and 12 months. Analogous to the analysis with viral load,
we use the linear model with log percent change in CD4 count, and express the effects as how
many times larger the average percent change is for the HIV+/FIL+ group than for the HIV+
/FIL- group. We find that there are no significant differences between the groups: at 1 year
(1.10; 95% CI 0.88, 1.38; p = 0.40) (Figs. 2 and 4), 3 months (0.99; 95% CI 0.82, 1.20; p = 0.92),
and 6 months (1.05; 95% CI 0.89, 1.24; p = 0.55).
Hemoglobin was assessed at 1, 3, 6 and 12 months. Again we use the linear model with log
percent change in hemoglobin, and express the effects as how many times larger the average
percent change is for the HIV+/FIL+ group than for the HIV+/FIL- group. We find that there
are significant differences between the groups at 1 year (1.08; 95% CI 1.02, 1.15; p = 0.01)
(Fig. 4 C-E). We do not see those significant effects at other times: 1 month (1.00; 95% CI 0.96,
1.03; p = 0.78), 3 months (1.01; 95% CI 0.95, 1.07; p = 0.78), and 6 months (1.04; 95% CI 0.99,
1.08; p = 0.11).
To examine the efficacy of single dose DEC/Alb in HIV+/FIL+ patients, quantitation of cir-
culating filarial antigen (CFA) levels was assessed at baseline and at 1 year in those for whom
samples were available (n = 12). The GM CFA level in those who were positive at baseline was
1123 IU/ml (95% CI 590–2138); at 1 year, that level had decreased to 534 IU/ml (95% CI 235–
1215) (p = 0.03 WSR) (Fig. 5). Only 2 subjects who were CFA positive at the start of the study
became negative after 1 year. No CFA negative subjects became positive at the end of the study.
Treated filaria positive subjects also saw a decrease in the GM filaria-specific IgG and IgG4.
IgG decreased by 43% (from 40.4 μg/ml (CI 25–64) at baseline to 23.7 μg/ml (CI 17–32) at
1 year (p = 0.0008) and IgG4 decreased by 31%, although not statistically significant
(p = 0.1514): from 0.65 ng/ml (CI 0.19–2.2) baseline to 0.52 ng/ml (CI 0.16–1.7) at one year
(Fig. 5).
Fig 3. HIV viral load by over time by individual.HIV VL at baseline and 1 year in HIV+ /FIL+ individuals (A) and HIV+/FIL- individuals (B).
doi:10.1371/journal.pntd.0003622.g003
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Fig 4. CD4 counts and hemoglobin levels over time. CD4 counts (A andB) and Hemoglobin levels (Hgb) (C andD) at baseline and 1 year between HIV+ /
FIL+ individuals (A, C) and HIV+/FIL- individuals (B, D). E. Hemoglobin percent change at 1 year between HIV+/FIL+ and HIV+/FIL- individuals.
doi:10.1371/journal.pntd.0003622.g004
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PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0003622 March 20, 2015 9 / 13
Discussion
In this study, we attempted to look at the progression of HIV disease in patients withW. ban-
crofti/HIV co-infection compared with those with HIV alone after a one-time treatment with
DEC/Alb, the standard therapy used worldwide (except in Africa) for mass drug administra-
tion programs. In addition, we also looked at biomarkers as surrogates for disease progression
(CD4 count, viral load). We found no difference in the clinical outcomes of the subjects one
year after treatment. We did find a transient and significant increase in viral loads in those
Wb/HIV co-infected subjects not on ART after 1 month, though this difference in VLs between
the Wb-infected and -uninfected HIV+ subjects equalized for the remainder of the study.
When we examined CD4 counts at 3, 6 and 12 months, or viral loads and hemoglobin values at
1, 3, 6, and 12 months we found no difference between the 2 groups with the exception of
higher hemoglobin values in the co-infected group at 1 year. The protective effect of filarial in-
fection on infection-related anemia is lent support by a study of filarial/malaria co-infection in
Africa [22].
In the HIV+/FIL+ subjects, circulating filaria antigen levels and filaria-specific IgG and
IgG4 were lower in at 1 year than at baseline (although this did not achieve significance for the
IgG4), suggesting that the treatment was effective in decreasing filarial antigen load.
The present study has several limitations, the most significant being the small sample size.
We found a much lower than expected rate ofW. bancrofti positivity in the HIV population in
and around Chennai, although our sample size calculations were based on our 2004 prevalence
data in which we found that 9.5% of HIV positive subjects were filarial also antigen positive
[16]. India, like other LF endemic countries of the world, is participating in the Global Program
to Eliminate Lymphatic Filariasis (GPELF), and is distributing single dose diethylcarbamazine
(DEC) and albendazole on a population-wide level in some endemic regions. In the period
leading up to and during the study, there was a large drop in the prevalence ofW. bancrofti in-
fection in the population with little transmission occurring in the urban areas from which the
patients were recruited. It is possible that the MDA programs have lowered the prevalence and
incidence of lymphatic filariasis infection to levels much lower than we had seen previously.
At the time the study was planned, India was just starting to use ART. By the time we had
enrolled all of our subjects and controls,>50% of them were on ARTs. While this was a distinct
benefit to our subjects, it did make it difficult for us to see a difference in viral loads between
subjects and controls since many of them were already optimally virally suppressed at baseline.
Finding a difference in the course of HIV through treatment of a concomitant helminth in-
fection is quite difficult [13,15]. However, in one randomized blinded placebo controlled cross-
over study in Tanzania of 34 HIV+ individuals, there was a significant salutary effect on VL at
Fig 5. A.Wuchereria bancrofti antigen and antibody levels over time. CirculatingWuchereria bancrofti antigen levels in HIV+/FIL+ individuals at
baseline and 1 year.B. BMA-specific IgG in HIV+/FIL+ subjects at baseline and 1 year. C. Total IgG4 levels in HIV+/FIL+ subjects at baseline and 1 year.
doi:10.1371/journal.pntd.0003622.g005
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12 week in filarial-infected individuals at 12 weeks [14]. ARVs were not used, a potential differ-
ence between this study and the present study.
Other groups have looked at the interactions with HIV and other non-filarial helminth in-
fections with mixed findings [4,5,10,11,23–28]. Two studies have shown that anthelmintics de-
creased HIV viral load in helminth-infected HIV+ adults [4,14] whereas others have shown
just the opposite [5]. In most other studies there has been demonstrated little to no difference
in viral load after anthelmintic treatment [6–8].
The effects of helminth coinfection on CD4 counts in HIV-coinfected subjects are also con-
flicting. In several studies in Africa, the presence of helminth infection has been shown to ad-
versely affect CD4 counts [26,28,29], although other studies have shown either a protective
effect by helminths on CD4 counts [24,30] or no effect whatsoever [7,24,31]. A study from
Uganda showed no overall effect of empiric deworming in HIV positive patients, however fe-
male patients who received deworming had a greater increase in CD4 count at 1 year that was
not sustained at 2–3 years. In addition, women had an increase in hemoglobin after deworming
that was not seen in men [9]. Studies of HIV and filarial co-infection in the future will be in-
creasingly difficult as the prevalence of filarial infections decrease and more patients with HIV
infection receive ART. Future studies trying to examine this issue will be limited to areas of
high prevalence of both infections or as sub-studies within large cohorts in order to achieve a
sample size that can address some of the remaining questions.
In conclusion, our study has clearly demonstrated thatW. bancrofti infection, the most
prevalent filarial infection of humans, failed to influence HIV-related clinical status, VL or
CD4 counts at baseline and following treatment with DEC/ALB though there was an apparent
filarial-induced increase in VL after DEC/ALB in ART-naive coinfected individuals. Our data
suggest that like with vaccinations in HIV-infected individuals that the benefits of MDA inW.
bancrofti and other related infections far outweigh a miniscule transient risk in parasite/
HIV coinfections.
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